Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02931838
Registration number
NCT02931838
Ethics application status
Date submitted
3/10/2016
Date registered
13/10/2016
Date last updated
27/11/2020
Titles & IDs
Public title
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
Query!
Scientific title
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Query!
Secondary ID [1]
0
0
IM011-011
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Psoriasis
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Experimental: BMS-986165 Dose 1 - Specified dose of BMS-986165 on specified days.
Experimental: BMS-986165 Dose 2 - Specified dose of BMS-986165 on specified days.
Experimental: BMS-986165 Dose 3 - Specified dose of BMS-986165 on specified days.
Experimental: BMS-986165 Dose 4 - Specified dose of BMS-986165 on specified days.
Experimental: BMS-986165 Dose 5 - Specified dose of BMS-986165 on specified days.
Placebo comparator: Placebo - Specified dose of Placebo for BMS-986165 on specified days.
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) on Day 85 (Week 12)
Query!
Assessment method [1]
0
0
Psoriasis Area and Severity Index (PASI) 75 response: patients who achieved = 75% improvement (reduction) in PASI score compared to baseline were defined as PASI 75 responders. PASI scores can range from 0, corresponding to no signs of psoriasis up to theoretical maximum of 72.0, which means a higher PASI score reflects a higher psoriasis activity.
Query!
Timepoint [1]
0
0
Day 1 to Day 85
Query!
Primary outcome [2]
0
0
Number of Participants With Adverse Events
Query!
Assessment method [2]
0
0
The safety and tolerability of BMS-986195 as assessed by the number of subjects with adverse events (AEs); number of subjects with serious adverse events (SAEs); number of subjects with adverse events leading to discontinuation
Query!
Timepoint [2]
0
0
Day 1 to day 115
Query!
Secondary outcome [1]
0
0
Percentage of Participants on Day 85 With PASI-50, PASI-90, PASI-100.
Query!
Assessment method [1]
0
0
Percentage of patients achieving Psoriasis Area and Severity Index (PASI) 50, PASI 90 and PASI 100 responses on Day 85. PASI 50 response: patients who achieved = 50% improvement (reduction) in PASI score compared to baseline were defined as PASI 50 responders. PASI 90 response: patients who achieved = 90% improvement (reduction) in PASI score compared to baseline were defined as PASI 90 responders. PASI 100 response: patients who achieved = 100% improvement (reduction) in PASI score compared to baseline were defined as PASI 100 responders. PASI scores can range from 0, corresponding to no signs of psoriasis up to theoretical maximum of 72.0, which means a higher PASI score reflects a higher psoriasis activity.
Query!
Timepoint [1]
0
0
Day 1 to Day 85
Query!
Secondary outcome [2]
0
0
Percentage of Participants on Day 85 With sPGA Score of 0 or 1 (sPGA0/1 Response Rate).
Query!
Assessment method [2]
0
0
Percentage of participants achieving a clear (0) or almost clear (1) status on the Static Physician Global Assessment (sPGA) on Day 85. This index evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The assessment was scored on a scale of 0 to 5, where 0 = clear, with no evidence of plaque elevation, erythema, or scale, and 5 = severe induration, erythema, and scaling.
Query!
Timepoint [2]
0
0
Day 1 to Day 85
Query!
Secondary outcome [3]
0
0
Change From Baseline in DLQI Scores on Day 85
Query!
Assessment method [3]
0
0
The DLQI is a participant reported quality of life index which consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week. Each question is scored on a scale of 0 to 3 by a tick box: "not at all", "a little", "a lot", or "very much". The scores are summed, giving a range from 0 (no impairment of life quality) to 30 (maximum impairment)
Query!
Timepoint [3]
0
0
Day 1 to Day 85
Query!
Secondary outcome [4]
0
0
Change From Baseline in BSA on Day 85
Query!
Assessment method [4]
0
0
Measurement of psoriasis body surface area (BSA) involvement is estimated using the handprint method with the size of a patient's handprint representing \~1% of body surface area involved.The total BSA = 100% with breakdown by body region as follows: head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), trunk including axillae and groin = 30% (30 handprints), lower extremities including buttocks = 40% (40 handprints). A decrease from Baseline indicates improvement. Change from Baseline was calculated as Baseline score - Day 85 score; a positive change from Baseline therefore indicates improvement.
Query!
Timepoint [4]
0
0
Day 1 to Day 85
Query!
Secondary outcome [5]
0
0
Trough Observed Plasma Concentration of BMS-986165 (Ctrough)
Query!
Assessment method [5]
0
0
Pharmacokinetics of BMS-986165 were derived from plasma concentration versus time data. Ctrough= Trough observed plasma concentration
Query!
Timepoint [5]
0
0
Days 8, 15, 29, 57, 85
Query!
Eligibility
Key inclusion criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
* Male and female, ages 18 to 70 years
* Diagnosis of plaque psoriasis for 6 months
* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test, must not be pregnant, lactating, breastfeeding or planning pregnancy
* Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment plus 5 half-lives of the study drug plus 90 days.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
70
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Any significant acute or chronic medical illness
* Blood transfusion within 4 weeks of study drug administration
* Inability to tolerate oral medication
* Positive hepatitis-B (HBV) surface antigen
* Positive hepatitis-C (HCV) antibody
* Any history or risk for tuberculosis (TB)
* Any major illness/condition or evidence of an unstable clinical condition
* Chest X-ray findings suspicious of infection at screening
* has received ustekinumab, secukinumab or ixekizumab within 6 months of first administration of study medication
* Has received anti-Tumor Necrosis Factor (TNF) inhibitor(s) within 2 months of first administration of study medication
* Has received Rituximab within 6 months of first administration of study medication
* Topical medications/treatments for psoriasis within 2 weeks of the first administration of any study medication
* Any systemic medications/treatments for psoriasis within 4 weeks of the first administration of any study medication
Other protocol defined inclusion/exclusion criteria could apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
15/11/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
16/11/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
268
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Local Institution - Kogarah
Query!
Recruitment hospital [2]
0
0
Local Institution - Wolloongabba
Query!
Recruitment hospital [3]
0
0
Local Institution - Melbourne
Query!
Recruitment hospital [4]
0
0
Local Institution - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
4102 - Wolloongabba
Query!
Recruitment postcode(s) [3]
0
0
3053 - Melbourne
Query!
Recruitment postcode(s) [4]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Georgia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Indiana
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New Hampshire
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
North Carolina
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Oklahoma
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
South Dakota
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Tennessee
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Texas
Query!
Country [12]
0
0
Canada
Query!
State/province [12]
0
0
Alberta
Query!
Country [13]
0
0
Canada
Query!
State/province [13]
0
0
British Columbia
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
Ontario
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
Quebec
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
Dresden
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
Gera
Query!
Country [18]
0
0
Germany
Query!
State/province [18]
0
0
Hamburg
Query!
Country [19]
0
0
Germany
Query!
State/province [19]
0
0
Kiel
Query!
Country [20]
0
0
Germany
Query!
State/province [20]
0
0
Luebeck
Query!
Country [21]
0
0
Germany
Query!
State/province [21]
0
0
Mahlow
Query!
Country [22]
0
0
Germany
Query!
State/province [22]
0
0
Mainz
Query!
Country [23]
0
0
Germany
Query!
State/province [23]
0
0
Schwerin
Query!
Country [24]
0
0
Germany
Query!
State/province [24]
0
0
Stuttgart
Query!
Country [25]
0
0
Japan
Query!
State/province [25]
0
0
Aichi
Query!
Country [26]
0
0
Japan
Query!
State/province [26]
0
0
Fukuoka
Query!
Country [27]
0
0
Japan
Query!
State/province [27]
0
0
Hokkaido
Query!
Country [28]
0
0
Japan
Query!
State/province [28]
0
0
Hyogo
Query!
Country [29]
0
0
Japan
Query!
State/province [29]
0
0
Kyoto
Query!
Country [30]
0
0
Japan
Query!
State/province [30]
0
0
Tochigi
Query!
Country [31]
0
0
Japan
Query!
State/province [31]
0
0
Tokyo
Query!
Country [32]
0
0
Japan
Query!
State/province [32]
0
0
Kumamoto
Query!
Country [33]
0
0
Japan
Query!
State/province [33]
0
0
Osaka
Query!
Country [34]
0
0
Latvia
Query!
State/province [34]
0
0
Daugavpils
Query!
Country [35]
0
0
Latvia
Query!
State/province [35]
0
0
Riga
Query!
Country [36]
0
0
Latvia
Query!
State/province [36]
0
0
Ventspils
Query!
Country [37]
0
0
Mexico
Query!
State/province [37]
0
0
Jalisco
Query!
Country [38]
0
0
Mexico
Query!
State/province [38]
0
0
Nuevo LEON
Query!
Country [39]
0
0
Poland
Query!
State/province [39]
0
0
Krakow
Query!
Country [40]
0
0
Poland
Query!
State/province [40]
0
0
Lodz
Query!
Country [41]
0
0
Poland
Query!
State/province [41]
0
0
Lublin
Query!
Country [42]
0
0
Poland
Query!
State/province [42]
0
0
Osielsko
Query!
Country [43]
0
0
Poland
Query!
State/province [43]
0
0
Siedlce
Query!
Country [44]
0
0
Poland
Query!
State/province [44]
0
0
Skierniewice
Query!
Country [45]
0
0
Poland
Query!
State/province [45]
0
0
Warszawa
Query!
Country [46]
0
0
Poland
Query!
State/province [46]
0
0
Wroc?aw
Query!
Country [47]
0
0
Poland
Query!
State/province [47]
0
0
Wroclaw
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Bristol-Myers Squibb
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated with BMS-986165
Query!
Trial website
https://clinicaltrials.gov/study/NCT02931838
Query!
Trial related presentations / publications
Thaci D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatol Ther (Heidelb). 2022 Feb;12(2):495-510. doi: 10.1007/s13555-021-00649-y. Epub 2022 Jan 13. Catlett IM, Hu Y, Gao L, Banerjee S, Gordon K, Krueger JG. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022 Jun;149(6):2010-2020.e8. doi: 10.1016/j.jaci.2021.11.001. Epub 2021 Nov 10. Papp K, Gordon K, Thaci D, Morita A, Gooderham M, Foley P, Girgis IG, Kundu S, Banerjee S. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. N Engl J Med. 2018 Oct 4;379(14):1313-1321. doi: 10.1056/NEJMoa1806382. Epub 2018 Sep 11.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/38/NCT02931838/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/38/NCT02931838/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT02931838
Download to PDF